Stockscreener 앱 받기
6.39
1.24%
-0.07
전일 마감가:
$6.46
열려 있는:
$6.46
하루 거래량:
12,798
Relative Volume:
0.01
시가총액:
$302.05M
수익:
-
순이익/손실:
$-8.99M
주가수익비율:
-33.67
EPS:
-0.1898
순현금흐름:
$-3.94M
1주 성능:
+10.76%
1개월 성능:
+12.32%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.23
$6.585
1주일 범위
$5.26
$7.10
52주 변동 폭
$2.201
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
명칭
Polaryx Therapeutics Inc
전화
201-940-7236
주소
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
6.38 | 305.84M | 0 | -8.99M | -3.94M | -0.1898 |
VRTX
Vertex Pharmaceuticals Inc
|
441.17 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
833.10 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.31 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.58 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 개시 | Maxim Group | Buy |
Polaryx Therapeutics Inc 주식(PLYX)의 최신 뉴스
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - The Manila Times
A rare-disease biotech, Polaryx, just won a pediatric care award - Stock Titan
Number of employees of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView — Track All Markets
PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView — Track All Markets
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics, Inc. News — NASDAQ:PLYX - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Polaryx Therapeutics, Inc. (PLYX) stock price, news, quote and history - Yahoo Finance UK
PLYX: Polaryx Therapeutics, Inc.Options Chain - Zacks Investment Research
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - Bitget
Polaryx to webcast Needham healthcare presentation on Apr. 16 - Stock Titan
Polaryx Therapeutics Inc (NASDAQ: PLYX)Share Price - intelligentinvestor.com.au
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disea - AD HOC NEWS
Polaryx Therapeutics: Advancing Innovative Therapies for Rare Pediatric Lysosomal Storage Disorders (LSDs) - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) outlines rare pediatric LSD pipeline - Stock Titan
PLYX: Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026 - TradingView
Polaryx Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Polaryx Therapeutics, Inc.(NasdaqCM: PLYX) added to S&P TMI Index - marketscreener.com
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa
Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - tipranks.com
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com
Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times
FDA Fast Track for PLX‑200 targeting rare pediatric disorder - Stock Titan
Should I buy Polaryx Therapeutics, Inc. (PLYX) - Zacks Investment Research
Polaryx Therapeutics Stock Rises Amidst Key Clinical Trials Development - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics Stock Surges With New Phase Trial Decision - StocksToTrade
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget
Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? - Asianet Newsable
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
PLYX Forecast, Price Target & Analyst Ratings | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
Polaryx Therapeutics Inc (PLYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
1.62%
자본화:
|
볼륨(24시간):